GlaxoSmithKline signed an agreement and obtained the exclusive license of hepatitis B drug JNJ-3989
六月清晨搅
发表于 2023-11-1 14:00:47
297
0
0
On October 31st local time, GlaxoSmithKline and Arrowhead Pharmaceuticals announced that they had reached an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson&Johnson, to transfer the global exclusive further development and commercialization rights of JNJ-3989 to GlaxoSmithKline. JNJ-3989 was originally authorized by Yang Sen from Arrowhead in 2018. After the transaction is completed, GlaxoSmithKline will be responsible for making a total advance payment of approximately $1 billion and potential payments to Janssen Pharmaceuticals and Arrowhead. JNJ-3989 is an ongoing siRNA therapy drug for the treatment of chronic hepatitis B.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Geely Automobile and STMicroelectronics Sign a Long Term Supply Agreement for SiC
- Abbey and Mingji Biotechnology sign a license agreement to jointly develop FG-M701
- Boeing reaches agreement with largest union to avoid strike
- Guoyin Jinzhu: Signed an aircraft purchase agreement with Boeing to purchase 50 737-8 aircraft
- Tianjing Biotechnology and Sanofi have reached an authorization agreement with a potential total price of up to 200 million euros
- OPEC+reportedly strengthens supervision and vows to reshape the authority of the production reduction agreement
- Nokia and Chunghwa Telecom reach extension agreement on 5G Advanced
- Sanofi and Jixing reach agreement on Aficamten in Greater China market
- Sanofi and Jixing announce agreement on Aficamten in Greater China market
- Shanghai Boeing and Premia Airlines sign long-term maintenance agreement